US President Donald Trump threatened steep tariffs on generic drugmakers. He stated medicines must be manufactured locally or face significant import duties. Swiss firm Sandoz will continue discussions with policymakers on this matter. The company is assessing implications for its manufacturing operations and future investments. This move aims to reverse offshore production and could increase drug prices.

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the…

US President Donald Trump on Tuesday announced a phased tariff regime on imported generic medicines, saying they will continue to enter the United States duty-free for two years…

Trump has been pressuring drugmakers through his most-favored-nation drug pricing policy to lower prices to what people pay in other high-income countries.

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…

US President Donald Trump threatened steep tariffs on generic drugmakers. He stated medicines must be manufactured locally or face significant import duties. Swiss firm Sandoz…